Skip to content

A clinical trials of Rapamycin cream in the treatment of pagets disease

A clinical trials of Rapamycin cream in the treatment of pagets disease

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800014979
Enrollment
Unknown
Registered
2018-02-26
Start date
2018-02-26
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pagets disease

Interventions

Case series:Topical rapamycin cream

Sponsors

Shanghai Skin Disease Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1. Aged over 18 years old, male or female; 2. patients need to have a relatively single clinical features and demographic common features; 3. Subjects fully understand the patient's notice, signed informed consent; 4. The duration of more than 3 months; 5. According to a comprehensive diagnosis, the diagnosis of the disease.

Exclusion criteria

Exclusion criteria: 1. Those who refuse to sign an informed consent belong to the category of the standard; 2. Failure to sign the informed consent will make the study less feasible; 3. The presence of comorbidities or co-morbidities, poor general condition, and serious illness leading to death before the end of the clinical trial falls within the criteria; 4. Exclusion criteria restrict certain cases to enrollment. The purpose is to increase the safety and feasibility of the study, including "informed consent" as an exclusion criterion and excluding cases that refused to sign an informed consent, in line with medical ethics requirements.

Design outcomes

Primary

MeasureTime frame
Histopathology Biopsy;

Countries

China

Contacts

Public ContactLiu Yeqiang

Shanghai Skin Disease Hospital

lyqdoctor@163.com+86 18017336841

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026